GI
ZVRA icon

GAMMA Investing’s Zevra Therapeutics ZVRA Stock Holding History

GAMMA Investing’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.97K Buy
362
+64
+21% +$758 ﹤0.01% 3747
2026
Q2 		$4.27K Hold
298
– – ﹤0.01% 3536
2026
Q1 		$2.78K Buy
298
+24
+9% +$216 ﹤0.01% 3566
2025
Q4 		$2.46K Sell
274
-86
-24% -$813 ﹤0.01% 3544
2025
Q3 		$3.42K Buy
360
+71
+25% +$712 ﹤0.01% 3312
2025
Q2 		$2.55K Sell
289
-787
-73% -$6.39K ﹤0.01% 3335
2025
Q1 		$8.06K Buy
1,076
+1,037
+2,659% +$8.24K ﹤0.01% 2857
2024
Q4 		$325 Sell
39
-94
-71% -$802 ﹤0.01% 3656
2024
Q3 		$923 Buy
+133
New +$903 ﹤0.01% 3279

Other funds holding ZVRA

MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

GAMMA Investing's ZVRA Position: Q3 2026 in Review

GAMMA Investing increased its Zevra Therapeutics (ZVRA) stake by 21% in Q3 2026, buying an estimated $758 and bringing the position to 362 shares worth $3.97K. The position accounts for ﹤0.01% of the portfolio, ranked #3747.

GAMMA Investing first reported a position in ZVRA in Q3 2024 and has held it in 9 quarters since. The position peaked at $8.06K in Q1 2025. 4 funds tracked by Wall St. Rank hold ZVRA as of Q3 2026.

  • GAMMA Investing held 362 shares of Zevra Therapeutics worth $3.97K as of Q3 2026.
  • GAMMA Investing bought 64 Zevra Therapeutics shares in Q3 2026, an estimated $758.
  • Zevra Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3747 holding.
  • GAMMA Investing first reported a position in Zevra Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • GAMMA Investing's Zevra Therapeutics position peaked at $8.06K in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.